|
1
|
National Collaborating Centre for Mental
Health: Schizophrenia: The NICE Guideline on Core Interventions in
the Treatment and Management of Schizophrenia in Adults in Primary
and Secondary Care (updated edition). The British Psychological
Society and the Royal College of Psychiatrists. London, 2010.
|
|
2
|
Moore TA, Buchanan RW, Buckley PF, Chiles
JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller
DD, et al: The Texas Medication Algorithm Project antipsychotic
algorithm for schizophrenia: 2006 update. J Clin Psychiatry.
68:1751–62. 2007.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Correll C, Rummel-Kluge C, Corves C, Kane
J and Leucht S: Antipsychotic combinations vs. monotherapy in
schizophrenia: A meta-analysis of randomized controlled trials.
Schizophr Bull. 35:443–457. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Jones PB, Barnes TR, Davies L, Dunn G,
Lloyd H, Hayhurst K, Murray R, Markwick A and Lewis S: Randomized
controlled trial of the effect on Quality of Life of second- vs.
first generation antipsychotic drugs in schizophrenia: Cost Utility
of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS
1). Arch Gen Psychiatry. 63:1079–1087. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lieberman JA, Stroup TS, McEvoy JP, Swartz
M, Rosenheck R, Perkins D, Keefe R, Davis S, Davis C, Lebowitz B,
et al: Effectiveness of antipsychotic drugs in patients with
chronic schizophrenia. N Engl J Med. 353:1209–1223. 2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Baandrup L, Allerup P, Lublin H,
Nordentoft M, Peacock L and Glenthoj B: Evaluation of a
multifaceted intervention to limit excessive antipsychotic
co-prescribing in schizophrenia out-patients. Acta Psychiatr Scand.
122:367–374. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Clark RE, Bartels SJ, Mellman TA and
Peacock WJ: Recent trends in antipsychotic combination therapy of
schizophrenia and schizoaffective disorder: Implications for state
mental health policy. Schizophr Bull. 28:75–84. 2002.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ganguly R, Kotzan JA, Miller LS, Kennedy K
and Martin BC: Prevalence, trends, and factors associated with
antipsychotic polypharmacy among Medicaid-eligible schizophrenia
patients, 1998-2000. J Clin Psychiatry. 65:1377–1388.
2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Paton C, Lelliott P, Harrington M, Okocha
C, Sensky T and Duffett R: Patterns of antipsychotic and
anticholinergic prescribing for hospital inpatients. J
Psychopharmacol. 17:223–229. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lung SLM, Lee HME, Chen YHE, Chan KWS,
Chang WC and Hui LMC: Prevalence and correlates of antipsychotic
polypharmacy in Hong Kong. Asian J Psychiatr. 33:113–120.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Suokas J, Suvisaari J, Haukka J, Korhonen
P and Tiihonen J: Description of long-term polypharmacy among
schizophrenia outpatients. Soc Psychiatry Psychiatr Epidemiol.
48:631–638. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Santone G, Bellantuono C, Rucci P, Picardi
A, Preti A and de Girolamo G: Patient characteristics and process
factors associated with antipsychotic polypharmacy in a nationwide
sample of psychiatric inpatients in Italy. Pharmacoepidemiol Drug
Saf. 20:441–449. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Tiihonen J, Taipale H, Mehtälä J,
Vattulainen P, Correll C and Tanskanen A: Association of
antipsychotic polypharmacy vs. monotherapy with psychiatric
rehospitalization among adults with schizophrenia. JAMA Psychiatry.
76:499–507. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fleischhacker W and Uchida H: Critical
review of antipsychotic polypharmacy in the treatment of
schizophrenia. Int J Neuropsychopharmacol. 17:1083–1093.
2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lin SK: Antipsychotic polypharmacy: A
dirty little secret or a fashion? Int J Neuropsychopharmacol.
23:125–131. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gallego J, Bonetti J, Zhang J, Kane J and
Correll C: Prevalence and correlates of antipsychotic polypharmacy:
A systematic review and meta-regression of global and regional
trends from the 1970s to 2009. Schizophr Res. 138:18–28.
2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Trifu S, Vlăduţi A and Trifu AI: Genetic
aspects in schizophrenia. Receptoral theories. Metabolic theories.
Rom J Morphol Embryol. 61:25–32. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Joukamaa M, Heliövaara M, Knekt P, Aromaa
A, Raitasalo R and Lehtinen V: Schizophrenia, neuroleptic
medication and mortality. Br J Psychiatry. 188:122–127.
2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tiihonen J, Suokas J, Suvisaari J, Haukka
J and Korhonen P: Polypharmacy with antipsychotics,
antidepressants, or benzodiazepines and mortality in schizophrenia.
Arch Gen Psychiatry. 69:476–483. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Baandrup L, Gasse C, Jensen V, Glenthoj B,
Nordentoft M, Lublin H, Fink-Jensen A, Lindhart A and Mortensen P:
Antipsychotic polypharmacy and risk of death from natural causes in
patients with schizophrenia: A population-based nested case-control
study. J Clin Psychiatry. 71:103–108. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mauri MC, Regispani F, Beraldo S,
Volonteri L, Ferrari V, Fiorentini A and Invernizzi G: Patterns of
clinical use of antipsychotics in hospitalized psychiatric
patients. Prog Neuropsychopharmacol Biol Psychiatry. 29:957–963.
2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sim K, Su A, Fujii S, Yang SY, Chong MY,
Ungvari G, Si T, Chung EK, Tsang HY, Chan YH, et al: Antipsychotic
polypharmacy in patients with schizophrenia: A multicentre
comparative study. Br J Clin Pharmacol. 58:178–183. 2004.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Morrato EH, Dodd S, Oderda G, Haxby DG,
Allen R and Valuck RJ: Prevalence, utilization patterns, and
predictors of antipsychotic polypharmacy: Experience in a multisite
Medicaid population, 1998-2003. Clin Ther. 29:183–195.
2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tapp A, Ernst Wood A, Secrest L, Erdmann
J, Cubberley L and Kilzieh N: Combination antipsychotic therapy in
clinical practice. Psychiatr Serv. 54:55–59. 2003.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Suzuki T, Uchida H, Watanabe K, Yagi G and
Kashima H: A clinical case series of switching from antipsychotic
polypharmacy to monotherapy with a second generation agent on
patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol
Psychiatry. 28:361–369. 2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Malandain L, Thibaut F, Grimaldi-Bensouda
L, Falissard B, Abenhaim L and Nordon C: Correlates and predictors
of antipsychotic drug polypharmacy in real-life settings: Results
from a nationwide cohort study. Schizophr Res. 192:213–218.
2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ito H, Koyama A and Higuchi T:
Polypharmacy and excessive dosing: Psychiatrists' perceptions of
antipsychotic drug prescription. Br J Psychiatry. 187:243–247.
2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Barnes TR and Paton C: Antipsychotic
polypharmacy in schizophrenia: Benefits and risks. CNS Drugs.
25:383–399. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Stahl S: Emerging guidelines for the use
of antipsychotic polypharmacy. Rev Psiquiatr Salud Ment. 6:97–100.
2013.PubMed/NCBI View Article : Google Scholar : (In English,
Spanish).
|
|
30
|
Trifu S, Tudor A and Rădulescu I:
Aggressive behavior in psychiatric patients in relation to hormonal
imbalance (Review). Exp Ther Med. 20:3483–3487. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
World Health Organization (WHO): The
ICD-10 Classification of Mental and Behavioural Disorders. Genève,
Switzerland: World Health Organization, 1993. https://apps.who.int/iris/handle/10665/37108.
|
|
32
|
Jaffe A and Levine J: Antipsychotic
medication coprescribing in a large state hospital system.
Pharmacoepidemiol Drug Saf. 12:41–48. 2003.PubMed/NCBI View
Article : Google Scholar
|
|
33
|
Lerma-Carrillo I, de Pablo Brühlmann S,
del Pozo ML, Pascual-Pinazo F, Molina J and Barca-García E:
Antipsychotic Polypharmacy in Patients With Schizophrenia in a
Brief Hospitalization Unit. Clin Neuropharmacol. 31:319–332.
2008.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Procyshyn RM, Kennedy NB, Tse G and
Thompson B: Antipsychotic polypharmacy: A survey of discharge
prescriptions from a tertiary care psychiatric institution. Can J
Psychiatry. 46:334–339. 2001.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Honer WG, Thornton AE, Chen EY, Chan RC,
Wong JO, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna PJ, Stip
E, et al: Clozapine alone versus clozapine and risperidone with
refractory schizophrenia. N Engl J Med. 354:472–482.
2006.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Pandurangi A and Dalkilic A: Polypharmacy
with second-generation antipsychotics: A review of evidence. J
Psychiatr Pract. 14:345–367. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zink M, Kuwilsky A, Krumm B and Dressing
H: Efficacy and tolerability of ziprasidone vs. risperidone as
augmentation in patients partially responsive to clozapine: A
randomised controlled clinical trial. J Psychopharmacol.
23:305–314. 2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Josiassen RC, Joseph A, Kohegyi E, Stokes
S, Dadvand M, Paing WW and Shaughnessy R: Clozapine augmented with
risperidone in the treatment of schizophrenia: A randomized,
double-blind, placebo-controlled trial. Am J Psychiatry.
162:130–136. 2005.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Freudenreich O, Henderson DC, Walsh JP,
Culhane MA and Goff D: Risperidone augmentation for schizophrenia
partially responsive to clozapine: A double-blind,
placebo-controlled trial. Schizophr Res. 92:90–94. 2007.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Stroup TS, McEvoy JP, Ring KD, Hamer RH,
LaVange L, Swartz M, Rosenheck R, Perkins D, Nussbaum A and
Lieberman JA: Schizophrenia Trials Network. A randomized trial
examining the effectiveness of switching from olanzapine,
quetiapine, or risperidone to aripiprazole to reduce metabolic
risk: Comparison of antipsychotics for metabolic problems (CAMP).
Am J Psychiatry. 168:947–956. 2011.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Fleischhacker WW, Heikkinen ME, Olie JP,
Landsberg W, Dewaele P, McQuade R, Loze JY, Hennicken D and
Kerselaers W: Effects of adjunctive treatment with aripiprazole on
body weight and clinical efficacy in schizophrenia patients treated
with clozapine: A randomized, double-blind, placebo-controlled
trial. Int J Neuropsychopharmacol. 13:1115–1125. 2010.PubMed/NCBI View Article : Google Scholar
|
